Exelixis appoints Dana Aftab as EVP R&D; Amy Peterson departs as CMO

EXELIXIS, INC.

Dana Aftab, Ph.D., promoted to EVP of R&D effective August 29, 2025; previously EVP Discovery & CSO.
Amy C. Peterson, M.D., concluded service as EVP Product Development and CMO on same date.
Dr. Peterson eligible for severance under Exelixis's Change in Control and Severance Benefit Plan.
No other officer changes disclosed; Dr. Aftab's compensation terms unchanged from prior proxy filing.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.